| Company Name: | BOC Sciences |
| Tel: | 1-631-504-6093 |
| Email: | sales@bocsci.com |
| Products Intro: |
Product Name:IKARUGAMYCIN
CAS:36531-78-9
|
| Company Name: | Guangzhou Isun Pharmaceutical Co., Ltd |
| Tel: | 020-39119399 18927568969 |
| Email: | isunpharm@qq.com, isunpharm@hotmail.com |
| Products Intro: |
Product Name:IkarugaMycin
CAS:36531-78-9
Purity:98% (HPLC) Package:25Mg; 1g; 100g; 500g |
| Company Name: | ChemStrong Scientific Co.,Ltd |
| Tel: | 0755 66853366 |
| Email: | sales@chem-strong.com; |
| Products Intro: |
Product Name:Ikarugamycin
CAS:36531-78-9
Purity:>99% by HPLC Package:0.5mg,2.5mg |
|
| | IKARUGAMYCIN Basic information |
| Product Name: | IKARUGAMYCIN | | Synonyms: | TU-6239 C3;IKARUGAMYCIN;14,17-Metheno-17H-as-indaceno[3,2-k][1,6]diazacycloheptadecine-9,16,18(1H)-trione;3-Ethyl-2,3,3a,5a,5b,6,10,11,12,13,14,15,20a,21,21a,21b-hexadecahydro-22-hydroxy-2-methyl-, (2R,3R,3aS,5aR,5bS,7Z,14S,19E,20aS,21aR,21bR)- | | CAS: | 36531-78-9 | | MF: | C29H38N2O4 | | MW: | 478.62 | | EINECS: | | | Product Categories: | Antibiotic | | Mol File: | 36531-78-9.mol |  |
| | IKARUGAMYCIN Chemical Properties |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 |
| | IKARUGAMYCIN Usage And Synthesis |
| Usage | Ikarugamycin is an unusual pentacyclic tetramic acid produced by Streptomyces phaeochromogenes, with potent activity against the protozoan, Trichomonas vaginalis, reported in 1972. Ikarugamycin also demonstrates selective Gram positive antibacterial activity, and anti-ucler activity possibly via inhibition of H. pylori. In addition, ikarugamycin inhibits the uptake of oxidized low-density lipoprotein in mouse macrophages, blocks PMA and Nef-mediated cell surface CD4 down-regulation, and inhibits clathrin-coated pit-mediated endocytosis. Importantly, ikarugamycin is emerging as a useful agent for studying the process of endocytosis. | | Usage | Ikarugamycin is an unusual pentacyclic tetramic acid produced by Streptomyces phaeochromogenes, with potent activity against the protozoan, Trichomonas vaginalis, reported in 1972. Ikarugamycin also demonstrates selective Gram positive antibacterial activity, and anti-ulcer activity possibly via inhibition of H. pylori. In addition, ikarugamycin inhibits the uptake of oxidized low-density lipoprotein in mouse macrophages, blocks PMA and Nef-mediated cell surface CD4 down-regulation, and inhibits clathrin-coated pit-mediated endocytosis. Importantly, ikarugamycin is emerging as a useful agent for studying the process of endocytosis. |
| | IKARUGAMYCIN Preparation Products And Raw materials |
|